Skip to main content
. 2022 Jan 31;32(1):29–39. doi: 10.1089/nat.2021.0043

Table 2.

Adverse Events Overview

 
Part 1
Combined Parts 1 and 2
AEs, n (%) Placebo (n = 4) Golodirsen (n = 8) Total golodirsen (n = 25)
Patients with ≥1 AE, n (%) 4 (100) 8 (100) 25 (100)
 Related to study drug 2 (50.0) 5 (62.5) 9 (36.0)
 Serious 0 0 4 (16.0)
 Leading to study drug discontinuation 0 0 0
Total AEs by severity, n 23 69 860
 Mild 22 68 831
 Moderate 1 1 24
 Severe 0 0 5

AE, adverse event.